Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation
Completed · Not applicable · NCT04580914
Conditions: Paroxysmal Atrial Fibrillation
At a glance
- Research payments reported, 2025
- $1,000
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 321
About the trial
- Sponsor
- Boston Scientific Corporation
- Tested
- Treatment with IntellaNav StablePoint Ablation Catheter (device)
- Dates
- Started 2021-04-12; completion 2023-06-21
- Results posted
- Yes
The NEwTON AF study is a multi-center, global, prospective, single arm study to establish the safety and effectiveness of the IntellaNav StablePoint Catheter and Force-Sensing System in subjects with symptomatic, drug refractory, recurrent paroxysmal atrial fibrillation.
From ClinicalTrials.gov, last updated 2025-01-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $1,000 in research payments for this study in 2025 (2 payments).
Products named: Clinical Trial Product
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jason Meyers, MD Cardiac Electrophysiology · West Des Moines, IA
- Sheetal Chandhok, MD Cardiology · Bryn Mawr, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Bryn Mawr Medical Specialists Association $750
- Mercyone Des Moines Medical Center, IA $250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.